Direxion Daily S&P Biotech Bull 3X ETF (LABU)
| Assets | $575.67M |
| Expense Ratio | 0.96% |
| PE Ratio | n/a |
| Forward PE | n/a |
| Shares Out | 2.62M |
| Dividend | $0.91 (0.36%) |
| Ex-Dividend Date | Dec 23, 2025 |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| Volume | 396,765 |
| Open | 236.00 |
| Previous Close | 242.25 |
| Day's Range | 236.00 - 253.75 |
| 52-Week Low | 108.90 |
| 52-Week High | 341.93 |
| Beta | 2.44 |
| Holdings | 173 |
| Inception Date | May 28, 2015 |
About LABU
Fund Home PageThe Direxion Daily S&P Biotech Bull 3X ETF (LABU) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times exposure to the S&P Biotechnology Select Industry Index. LABU was launched on May 28, 2015 and is issued by Direxion.
Top 10 Holdings
259.98% of assets| Name | Symbol | Weight |
|---|---|---|
| SPSIBI SWAP ASSET LEG | n/a | 53.40% |
| SPSIBI SWAP ASSET LEG | n/a | 49.02% |
| SPSIBI SWAP ASSET LEG | n/a | 44.64% |
| SPSIBI SWAP ASSET LEG | n/a | 35.45% |
| SPSIBI SWAP ASSET LEG | n/a | 30.05% |
| SPSIBI SWAP ASSET LEG | n/a | 15.23% |
| GOLDMAN FINL SQ TRSRY INST 506 | n/a | 14.17% |
| DREYFUS GOVT CASH MAN INS | n/a | 13.81% |
| SPSIBI SWAP ASSET LEG | n/a | 2.65% |
| Moderna, Inc. | MRNA | 1.56% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 23, 2025 | $0.90971 | Dec 31, 2025 |
| Sep 23, 2025 | $0.10273 | Sep 30, 2025 |
| Jun 24, 2025 | $0.21897 | Jul 1, 2025 |
| Mar 25, 2025 | $0.10714 | Apr 1, 2025 |
| Jun 25, 2024 | $0.15021 | Jul 2, 2024 |
| Mar 19, 2024 | $0.16064 | Mar 26, 2024 |
Performance
LABU had a total return of 100.54% in the past year, including dividends. Since the fund's inception, the average annual return has been -19.76%.
News
Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism
Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big p...
Where to Buy Booming Biotech ETFs
Discover why biotech stocks are surging despite large fund outflows. Monitor these three industry ETFs for "buy the dip" opportunities.
Jablonski: Biotech presents a good buying opportunity
Sylvia Jablonski of Direxion discusses why biotech stocks and ETFs are attractive right now, due to their cheapness relative to the rest of the market.